Table 1.

Selected marine natural compounds or derivatives that have been approved or entered into clinical trials in the past decades.

Compound	Source	Indications	Mechanisms	Clinical Trial
Cytarabine	Cryptotethia crypta	AML	DNA synthesis inhibition	Approved
Eribulin	Halichondria okadai	Breast cancer, liposarcoma	Prevention the formation of spindles and EMT, apoptosis induction	Approved
Marizomib	Salinispora tropica	MM	Selectively inhibiting 20S proteasome	Approved
Plitidepsin	Aplidium albican	Solid tumor, MM	Cell cycle arrest, apoptosis induction	Approved
Trabectedin	Ecteinascidia turbinata	Liposarcoma, leiomyosarcoma	Binding to guanine residues in the DNA groove to form protein adducts	Approved
Adcetris	Dolabella auricularia	Hodgkin’s lymphoma	Inhibiting tubulin formation, apoptosis induction	Approved
Zalypsis	Joruna funebris	Urothelial carcinoma, cervical carcinoma, MM	rendering DNA double strand breaks, cell cycle arrest, apoptosis induction	Phase II
OKI-179	Cyanobacterium, Symploca	Advanced solid tumors	Class I HDAC inhibition	Phase I

Abbreviations: HDAC: Histone Deacetylase; AML: Acute Myeloid Leukemia; EMT: Epithelial-Mesenchymal Transition; MM: Multiple Myeloma; MMPs: Matrix Metalloproteinases.